RhD discrepancies between current and historical results are problematic to resolve. The investigation of 10 discrepancies is reported here. STUDY DESIGN: Samples identified were those that reacted by automated gel technology and were negative with an FDA-approved reagent. Reactivity with a commercially available panel of monoclonal anti-D was performed. Genomic DNA was evaluated for RHD alleles with multiplex RHD exon polymerase chain reaction (PCR), weak D PCR-restriction fragment length polymorphism, and RHD exon 5 and 7 sequence analyses. 
R hD variants are classified for clinical purposes into one of three groups: partial D variants (including category), weak D types, or nonfunctional and D-elution alleles. 1 Partial D variants lack D antigen epitopes, 2 and weak D types generally present all D epitopes albeit some epitopes show variability depending on the monoclonal anti-D. 3, 4 Individuals who harbor partial D variant alleles have the potential to make alloanti-D, 5 whereas common weak D types do not pose such a risk. 6 The distinction is important because the appropriate assignment of D antigen status determines the selection of blood products and perinatal management to prevent anti-D hemolytic disease of the fetus and newborn.
The intent of FDA-approved anti-D serologic typing reagents is to ensure that the appropriate D antigen status is assigned, such that the most common partial D variants (e.g., DVI) are nonreactive by the immediate-spin (IS) tube test and therefore are classified as D-. Exceptions do exist, however, and in light of changing technologies and reagents along with the multitude of variants with weakened or altered expression, discrepancies are noted.
with assigning the appropriate D antigen status, so that the appropriate (D-or D+) blood products can be administered. Moreover, in an era of informed consent, the impact of a D antigen discrepancy can create confusion over the use of Rh immune globulin. 9 The D antigen is a 417 amino acid moiety with a tertiary conformation that can be described in a 30 epitope model. 10, 11 More than 175 alleles have been characterized at molecular level. 12 Some D variants have similar epitope profiles when evaluated with monoclonal anti-D reagents. For example, DBS, DFR, and some category DVa variants share some exon 5 amino acid replacements and some D epitopes. 13 For the most part, similar serologic profiles do not create a problem for the interpretation of D antigen status when a partial D variant is suspected. The DAR allele is one such allele that is at risk for anti-D alloimmunization due to the lack of D antigen epitopes. With the 37-epitope model, DAR is thought to lack epitopes 2, 4, 7, 10, 11, 17, 18, 21, 22, 23, and 31 to 35 and to have an altered expression for many of the remaining epitopes.
14 Thus, specific monoclonal anti-D reagents have become popular reagents to identify partial D variants quickly, which help clinicians make an informed decision on the appropriate D antigen status. Alternatively, molecular analyses including direct nucleotide sequencing have been used to resolve RHD discrepancies, although these specialized techniques have a less than ideal turnaround time. [15] [16] [17] [18] We evaluated a group of 10 patients who were identified on the basis of a D antigen discrepancy with historical records or tube test results. We evaluated the expression of the D antigen with three FDA-approved anti-D reagents and a panel of non-FDA-approved monoclonal anti-D reagents and performed molecular analyses to resolve the discrepancies. We show here that the DAR allele and category DVa variants have similar monoclonal anti-D profiles. More importantly, we show that an FDA-approved reagent can have variable reactivity with various examples of weak D types, and in some instances, these weak D types can mimic partial D variants in their monoclonal anti-D epitope profile.
MATERIALS AND METHODS

Sample selection
Samples were initially identified on the basis of a discrepancy between a newly implemented automated gel technology test (ProVue, Ortho Clinical Diagnostics, Raritan, NJ) and historical records. In all instances, the gel Rh typing test indicated that the patient was D+ when the patient's historical record was D-. Other discrepancies were noted when an IS tube test was performed to confirm the Rh type before the release of electronic crossmatchcompatible blood.
Serologic analysis
Once a discrepancy was noted with the automated gel test, the samples were further analyzed by IS tube test with two anti-D reagents (Gamma-clone, Immucor, Inc., Norcross, GA; BioClone, Ortho Clinical Diagnostics, Raritan, NJ) in accordance with the manufacturers' recommendations for the IS tube test. Hemagglutination was graded and scored as described by Marsh. 19 In addition, the red cells (RBCs) were tested with a panel of monoclonal antibodies (MoAbs) indicated as A through L (Alba Bioscience, Edinburgh, UK). Included in the serologic analysis of the discrepancies was a complete Rh C, c, E, e phenotype, with the most probable genotype method used to assign the Rh genotype.
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RHD molecular analyses
Samples with a discrepant IS tube test result were analyzed for partial D variants with a multiplex polymerase chain reaction (PCR) protocol for seven RHD-specific exons 3 through 7 and 9 and exon 10. 21, 22 Those samples with RHD-specific exons were further analyzed for the presence of weak D Type 1 through Type 3 by PCRrestriction fragment length polymorphism (RFLP). 3, 23, 24 Samples that could not be assigned an RHD allele were subjected to direct automated sequencing of RHD exon 5. 23 A separate PCR amplification product with the exon 7 primers alone was subjected to direct sequence analysis to evaluate the 1025-nucleotide position for presence of the DAR allele. Comparative analysis with the reference RHD sequence NM_016124 was performed with the pair-wise basic local alignment search tool (BLAST).
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RESULTS
Monoclonal anti-D pattern
The MoAbs were chosen on the basis of the potential to provide information for the presence of partial D phenotypes. Table 1 
Reactivity of DAR and weak D types
Multiplex RHD-specific PCR indicated that the two serologically DVa samples had nucleotide changes in exon 5 due to a lack of amplification of this exon. We found D antigen discrepancies between a recently implemented gel technology in our institution and historical records or the result of tube test anti-D performed as part of the electronic crossmatch process. We used a large series of monoclonal anti-D reagents to evaluate the epitope profiles of these samples as a way to resolve discrepancies. In addition, we performed a multiplex sequence-specific priming PCR, PCR-RFLP, and sequenced exon 5 to identify common partial and weak D types.
Our studies found that the DAR phenotype and the partial D category DVa have similar monoclonal anti-D epitope profiles. This observation is not surprising given the common nucleotide changes in exon 5 shared by these two partial D variants. The nucleotide change at position 1025 of exon 7 confirmed the presence of the DAR allele, and the assignment did not have an impact on the choice of blood products or perinatal care. Serologic reactivity with BioClone anti-D, however, showed a disparity for the two DAR samples. One sample reacted (score 5) and the other did not react with the IS test method. The most probable genotype of both samples was R or and because the assignment is based on probability, the disparity possibly could be explained on the basis of one sample representing the RoRo phenotype, that is, homozygous for RHD. For the monoclonal anti-D profile and molecular analyses to be consistent with the presence of two RHD alleles, however, both would have to represent the DAR allele as suggested in the product monograph. We have had one other Ror sample expressing DAR that did not Table 2 ).
An exhaustive evaluation of D antigen density and epitope distribution among partial D has been performed in the past. The most likely reason for the variable expression among similar weak D types is unknown. Aside from the variable expression known to exist for partial D, previous studies showed that the expression of the D antigen varies. 30, 31 Other than the cis-trans effect exerted in the presence of RHCe, 32 no molecular mechanism for this variation has been identified. Possibly, there are noncoding differences among similar variants that may affect the half life of the mRNA, or alternatively, there may be subtle differences in some other moiety of the Rh complex, which affects the expression of the D antigen as has been previously hypothesized. 30 In our opinion, tube tests have the highest degree of subjectivity and result in the most variability. The definition of "immediate spin" is difficult to define when one considers that samples can be tested alone or as part of a batch. Moreover, small differences in the testing temperature, protein concentration, and other technical factors such as minor centrifugation speed differences or how the RBC pellet is dislodged can affect the degree of agglutination and likely contribute to the variable results for manual tube tests even for repeat tests performed on the same sample.
The variation in expression and ultimately the D antigen status of patients who harbor alleles of weak D alleles still pose a challenge for the transfusion service. In our hands, a change in method (introduction of gel technology) resulted in Rh discrepancies. The data presented here of our investigations show that a serologic solution to the positive identification of weak and partial D variants is unlikely. Therefore, we recommend that samples yielding an IS tube test cutoff score of not more than 5 (i.e., Յ1+ hemagglutination) or a score of not more than 8 (i.e., Յ2+ hemagglutination) by gel technology, be considered Dfor the purpose of transfusion and Rh immune globulin prophylaxis.
Unfortunately, serology alone does not resolve the issue of those weak D types not at risk of making anti-D. Molecular tests that can distinguish common partial and weak D types provide the best solution to the resolution of an accurate D antigen status. In our small study, the D antigen status of 8 of 10 patients was resolved with three molecular tests. Future work should focus on improvements to the turnaround time for resolving Rh discrepancies.
